Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report.
Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report.
复制标题
DOI：
10.4254/wjh.v12.i12.1349
复制
发表时间：
2020-12-27
影响因子：
2.4
通讯作者：
Furukawa H
中科院分区：
文献类型：
--
作者：
Yokoo H;Takahashi H;Hagiwara M;Iwata H;Imai K;Saito Y;Matsuno N;Furukawa H
在既往未接受过全身化疗的不可切除肝细胞癌（HCC）患者中，乐伐替尼在预后和复发率方面不劣于索拉非尼。在接受乐伐替尼治疗的患者中，40%的病例实现了足够的肿瘤缩小，使潜在的手术成为可能。然而，这种手术的结果是未知的。我们报告了一个成功的病例，肝切除术治疗乐伐替尼治疗后复发性肝癌。一位69岁男性因肝第8段肝癌接受右前切除术。10个月后，他被发现有肝内肝癌复发，迅速增长到10厘米直径与胸骨骨转移。在确认乐伐替尼给药2个月后部分缓解后，进行了第二次肝切除术。病理检查显示80%的肿瘤坏死。该患者在乐伐替尼治疗期间未发生任何不良反应。术后25 d出院。在乐伐替尼治疗下继续给予骨转移放疗，患者在第二次肝切除术后存活1年。肝切除联合既往乐伐替尼治疗可改善复发性HCC患者的预后。
Lenvatinib has been shown to be noninferior to sorafenib regarding prognosis and recurrence rate in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic chemotherapy. In patients treated with lenvatinib, 40% of cases achieved sufficient tumor reduction to make potential surgery possible. However, the outcomes of such surgery are unknown. We report a successful case of hepatic resection for recurrent HCC after lenvatinib treatment. A 69-year-old man underwent right anterior sectionectomy for HCC in segment 8 of the liver. Ten months later, he was found to have an intrahepatic HCC recurrence that grew rapidly to 10 cm in diameter with sternal bone metastases. After confirming partial response to lenvatinib administration for 2 mo, a second hepatectomy was performed. Pathological examination showed that 80% of the tumor was necrotic. The patient did not develop any adverse effects under lenvatinib treatment. He was discharged at 25 d after surgery. Radiation therapy for bone metastases continued to be given under lenvatinib, and the patient has remained alive for 1 year after the second hepatectomy. The prognosis of patients with recurrent HCC may be improved by liver resection combined with prior lenvatinib therapy.
登录
查看更多内容
影响因子：
--
作者：
Kishi, Yoji;Saiura, Akio;Yamaguchi, Toshiharu
通讯作者：
Yamaguchi, Toshiharu
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
168.9
作者：
Bruix, Jordi;Qin, Shukui;Han, Guohong
通讯作者：
Han, Guohong
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen
影响因子：
1
作者：
Takeda, Kazuhisa;Tsurumaru, Yuji;Endo, Itaru
通讯作者：
Endo, Itaru